503A vs 503B: The Complete Framework for GLP-1 Compounding
Understanding FDA compounding designations, quality standards, and what certifications actually mean for your semaglutide or tirzepatide prescription.
503A pharmacies are traditional compounding pharmacies that fill patient-specific prescriptions and are primarily regulated by state boards of pharmacy. 503B outsourcing facilities are FDA-registered, can compound without individual prescriptions, must follow pharmaceutical manufacturing standards (cGMP), and are subject to federal inspections. Neither is inherently "better" — they serve different purposes with different oversight structures.
Why This Matters for GLP-1 Medications
If you're considering compounded semaglutide or tirzepatide, you'll likely encounter these terms. The pharmacy filling your prescription could be either a 503A traditional compounding pharmacy or a 503B outsourcing facility — and understanding the difference helps you evaluate the quality and legitimacy of your medication source.
This regulatory framework became especially relevant in 2024-2025 as the FDA declared semaglutide and tirzepatide shortages resolved, triggering enforcement actions against compounders who were still making "essentially copies" of approved drugs.
The Legal Framework: Where 503A and 503B Come From
A Brief History
The Food and Drug Administration Modernization Act established Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), creating a "safe harbor" for traditional pharmacy compounding under state regulation.
The Supreme Court struck down provisions of 503A related to advertising restrictions, creating regulatory uncertainty for years.
Contaminated steroid injections from New England Compounding Center cause 751 illnesses and 64 deaths across 20 states. The outbreak exposes gaps in compounding oversight.
The Drug Quality and Security Act responds to the outbreak by creating the new 503B "outsourcing facility" category and restoring validity to Section 503A by removing the unconstitutional advertising provisions.
FDA issues guidance documents, conducts hundreds of inspections, and continues developing regulatory clarity for both 503A and 503B compounders.
The new legislation was aimed at preventing future tragedies like we saw in 2012 and in many cases before then... [503B facilities] often engage in larger-scale, nationwide distribution with the potential to expose more patients to the risks associated with compounded drugs, compared to more traditional pharmacy compounders.— Scott Gottlieb, MD, FDA Commissioner, Congressional Testimony, January 2018
503A vs 503B: Side-by-Side Comparison
| Characteristic | 503A (Traditional Pharmacy) | 503B (Outsourcing Facility) |
|---|---|---|
| Primary Regulator | State Board of Pharmacy | FDA (federal) |
| FDA Registration | Not required | Required (voluntary to become 503B) |
| Prescription Required? | Yes — patient-specific prescription required | No — can compound without individual prescriptions |
| Manufacturing Standards | USP <795> (non-sterile) and USP <797> (sterile) | Current Good Manufacturing Practice (cGMP) |
| FDA Inspections | Only for cause (not routine) | Routine, risk-based inspections |
| Batch Size | Limited quantities; typically one prescription at a time | Large batches permitted |
| Distribution | Primarily in-state; interstate limited to 5% | Nationwide distribution allowed |
| Sales Destination | Dispensing to individual patients (home use) | Hospitals, clinics, other pharmacies, physician offices |
| Adverse Event Reporting | Not required to FDA (state requirements vary) | Required to FDA |
| Product Testing | Per USP standards (less extensive) | Must validate every process; multiple batch testing before release |
| Labeling Requirements | Basic prescription labeling | More extensive labeling requirements |
| "Essentially a Copy" Rule | Cannot compound essentially a copy of a "commercially available" drug | Cannot compound essentially a copy of an "approved" drug (unless on shortage list) |
What Each Designation Actually Means in Practice
503A Traditional Compounding Pharmacies
Section 503A pharmacies are what most people picture when they think "compounding pharmacy" — a licensed pharmacist in a state-licensed pharmacy preparing medications for specific patients based on individual prescriptions.
Key features according to FDA guidance:
- Must be compounded by a licensed pharmacist or physician
- Requires a valid patient-specific prescription
- Exempt from FDA new drug approval requirements
- Exempt from cGMP requirements (but must follow USP standards)
- Cannot use drug components withdrawn for safety/efficacy concerns
- Primarily regulated by state boards of pharmacy
503A pharmacies can do anticipatory compounding — preparing limited quantities before receiving prescriptions — but only based on established prescribing patterns with existing physician relationships.
503A pharmacies may distribute compounded products interstate, but if they haven't signed a Memorandum of Understanding (MOU) with FDA, interstate distribution cannot exceed 5% of total prescriptions dispensed. Most states have not signed the MOU.
503B Outsourcing Facilities
Section 503B facilities are a hybrid between traditional pharmacies and pharmaceutical manufacturers. They emerged from the 2013 DQSA specifically to enable larger-scale, higher-quality compounding with federal oversight.
Key features:
- Must voluntarily register with FDA as an outsourcing facility
- Can compound without individual patient prescriptions
- Must follow cGMP (Current Good Manufacturing Practice) requirements
- Subject to routine FDA inspections on a risk-based schedule
- Must report adverse events to FDA
- Must submit semi-annual reports on compounded products
- Can distribute nationwide without the 5% limit
503B facilities can sell to hospitals, health systems, physician offices, and — as of 2023 FDA guidance — to 503A pharmacies for dispensing to patients.
A 503B outsourcing facility is not a manufacturer. Products made by 503B facilities are not covered by the same product liability laws as FDA-approved manufactured drugs. They do not have NDAs (New Drug Applications) on file.
The "Essentially a Copy" Rule and Drug Shortages
Both 503A and 503B facilities are restricted from compounding drugs that are "essentially copies" of commercially available or approved drugs. The exact language differs:
- 503A: Cannot be "essentially a copy of a commercially available drug product"
- 503B: Cannot be "essentially a copy of an approved drug product"
The Shortage Exception
Here's where GLP-1 compounding gets complicated:
When a drug is on the FDA shortage list, both 503A and 503B facilities can compound it — even if it would otherwise be considered "essentially a copy." Once the shortage ends, there's a 60-day grace period for orders in process, after which compounding must stop unless there's another legal basis (like a clinical difference for an individual patient).
For GLP-1 medications specifically:
- Tirzepatide: Removed from shortage list December 2024
- Semaglutide: Removed from shortage list February 2025
Post-shortage, 503A pharmacies can still compound these medications with a valid prescription if the prescriber documents a clinical need that the commercial product cannot meet (such as a different dose, form, or the patient has allergies to inactive ingredients). 503B facilities face stricter limits since they don't require individual prescriptions.
Quality Standards: USP vs cGMP
USP Standards (503A)
The United States Pharmacopeia sets standards that 503A pharmacies must follow:
- USP <795>: Non-sterile compounding (creams, capsules, oral liquids)
- USP <797>: Sterile compounding (injectables like semaglutide)
- USP <800>: Hazardous drug handling
These chapters outline requirements for personnel training, facility design, environmental monitoring, ingredient sourcing, and documentation.
cGMP (503B)
Current Good Manufacturing Practice requirements are more extensive and are the same standards applied to pharmaceutical manufacturers. They include:
- Process validation for every product
- Multiple batch testing before release
- Stability testing
- Quality assurance oversight
- Vendor qualification and auditing
- More extensive documentation requirements
Certifications That Actually Matter
Beyond regulatory designation, several voluntary certifications can indicate quality commitment:
PCAB Accreditation
The Pharmacy Compounding Accreditation Board (now administered by ACHC) is the most recognized certification for compounding pharmacies.
What it means: The pharmacy underwent rigorous on-site inspection verifying compliance with USP standards, staff training, facility design, and quality processes.
Look for: PCAB Accredited® Compounding Pharmacy seal
LegitScript Certification
LegitScript verifies that online pharmacies and healthcare merchants are properly licensed and operating legally.
What it means: The pharmacy has verified state licensing, proper physician relationships (if telehealth), and meets legal requirements for online medication sales.
Required by: Google, Facebook, Microsoft for pharmacy advertising
State Board of Pharmacy License
The baseline requirement for any pharmacy operating in the United States.
What it means: The pharmacy is licensed in its home state and (if shipping across state lines) holds non-resident licenses in destination states.
How to verify: Check your state board of pharmacy's online license lookup
FDA 503B Outsourcing Facility
Registration with FDA as an outsourcing facility.
What it means: The facility is subject to federal inspections, cGMP requirements, and adverse event reporting.
How to verify: FDA's registered outsourcing facilities list
FDA Oversight Reality: What the Numbers Show
As of the FDA Commissioner's 2018 testimony, the agency had conducted close to 500 inspections of 503A and 503B facilities since 2013. The findings were concerning:
We have observed problematic conditions during the vast majority of these inspections and have overseen more than 150 recalls of compounded drugs and issued more than 180 warning letters... In some of its initial inspections, the agency found vermin, such as cockroaches, in the area where employees prepare for sterile processing; employees processing sterile drugs with exposed skin that sheds particles and bacteria; contamination, including bacteria and mold, in the environment where sterile drugs are produced.— Scott Gottlieb, MD, FDA Commissioner, Congressional Testimony, January 2018
More recent enforcement activity in 2025 specifically targeted GLP-1 compounders making misleading claims about FDA approval or "generic" versions. (See our full analysis: FDA Warning Letters: September 2025 Full Text)
What This Means for GLP-1 Patients
Questions to Ask Your Pharmacy
- "Are you a 503A or 503B facility?" — Understand the regulatory framework
- "Are you PCAB accredited?" — The gold standard for compounding quality
- "What is your state pharmacy license number?" — Verify they're properly licensed
- "Where do you source your active ingredients?" — Look for FDA-registered suppliers with Certificates of Analysis
- "How do you ensure sterility for injectables?" — They should reference USP <797> compliance
Red Flags
- Claims of selling "FDA-approved" compounded medications (compounded drugs are never FDA-approved)
- Marketing compounded semaglutide as "generic Ozempic" or "same as Wegovy"
- No requirement for a prescription from a licensed prescriber
- Unable or unwilling to provide license/certification information
- Prices that seem too good to be true compared to other compounding pharmacies
Neither 503A nor 503B is inherently "safer" — what matters is whether the facility follows its applicable standards, has proper licensing, and maintains quality certifications. A well-run 503A pharmacy with PCAB accreditation can produce high-quality compounds; a poorly-run 503B facility can have serious quality issues despite federal registration.
Sources
- FDA Commissioner Testimony: Examining Implementation of the Compounding Quality Act (January 30, 2018)
Find Properly Licensed GLP-1 Providers
Compare verified compounding pharmacies and telehealth providers with transparent licensing and pricing.
Medical Disclaimer: This article is for informational purposes only. All medication decisions should be made in consultation with a licensed healthcare provider.
Affiliate Disclosure: SourceGLP-1 may receive compensation from partner sites linked above. This does not influence our research or editorial content.